---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-043729"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2022-11-30T23:59:59+00:00"
generated_at: "2026-06-21T11:36:13.623001+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bionano completes acquisition of Purigen Biosystems for $32M cash, plus $32M earnout

## Summary
- Closed acquisition of Purigen Biosystems on Nov 30, 2022; upfront cash consideration ~$32M.
- Up to additional $32M in cash payable upon achievement of certain milestones.
- Purigen survives as a wholly owned subsidiary of Bionano Genomics.
- Consideration subject to customary adjustments for cash, debt, transaction expenses, and net working capital.
- Post-closing purchase price adjustment mechanism with escrow for potential adjustments.

## SEC filing metadata
- accession: 0001140361-22-043729
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2022-11-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000114036122043729/0001140361-22-043729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000114036122043729/brhc10044882_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-043729
- JSON: https://secwatch.observer/filing/0001140361-22-043729.json
- Plain text: https://secwatch.observer/filing/0001140361-22-043729.txt

## Key facts
- M&A Transactions
  Bionano Genomics, Inc. completed an acquisition involving Purigen Biosystems, Inc. for approximately $32.0 million in cash (closed 2022-11-30).
  - Action: acquisition
  - Counterparty: Purigen Biosystems, Inc.
  - Consideration: approximately $32.0 million in cash
  - Closing: 2022-11-30
  source text: the surviving corporation of the Merger and a wholly owned subsidiary of the Company. Pursuant to the Merger, the Company paid at closing upfront consideration of approximately $32.0 million in cash. The upfront consideration was subject to adjustment for, among other things, cash, unpaid indebtedness, unpaid transaction expenses and net working capital relative to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036122043729/0001140361-22-043729-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.